At the 2010 ACR Annual Scientific Meeting, a presentation showed that systemic inflammation and rheumatoid arthritis disease activity may contribute to the progression of atherosclerosis in people with RA. The progression may be modified favorably by TNF inhibitors and detrimentally by glucocorticoids. Read more...
The FDA approved Cymbalta on November 4, 2010 for the treatment of chronic musculoskeletal pain, including osteoarthritis and chronic low back pain. You may have heard of Cymbalta before now. The drug was first approved and used to treat major depressive disorder in 2004. Read more...
According to Bloomberg, injectable drugs used to treat rheumatoid arthritis (also commonly referred to as biologics) rake in $12 billion in annual sales. Pfizer is now developing a pill, called tasocitinib, that would rival the injectables -- if clinical trials conclude it is safe and effective and if it ultimately is approved by the FDA. Read more...
According to a report in the November 2 Annals of Internal Medicine, of 4,700 people who died during the time they served as study participants, 26% experienced pain in the two years before they died. In the last 4 months before death, those experiencing significant pain increased to 50%. Among people with arthritis, 60% reported significant pain in the last month of life compared to 26% without arthritis. Read more...
Sign up for more free newsletters on your favorite topics
You are receiving this newsletter because you subscribed to the About Arthritis newsletter. If you wish to change your email address or unsubscribe, please click here.
At the 2010 ACR Annual Scientific Meeting, a presentation showed that systemic inflammation and rheumatoid arthritis disease activity may contribute to the progression of atherosclerosis in people with RA. The progression may be modified favorably by TNF inhibitors and detrimentally by glucocorticoids. 
The FDA approved Cymbalta on November 4, 2010 for the treatment of chronic musculoskeletal pain, including osteoarthritis and chronic low back pain. You may have heard of Cymbalta before now. The drug was first approved and used to treat major depressive disorder in 2004. 
According to Bloomberg, injectable drugs used to treat rheumatoid arthritis (also commonly referred to as biologics) rake in $12 billion in annual sales. Pfizer is now developing a pill, called tasocitinib, that would rival the injectables -- if clinical trials conclude it is safe and effective and if it ultimately is approved by the FDA. 
According to a report in the November 2 Annals of Internal Medicine, of 4,700 people who died during the time they served as study participants, 26% experienced pain in the two years before they died. In the last 4 months before death, those experiencing significant pain increased to 50%. Among people with arthritis, 60% reported significant pain in the last month of life compared to 26% without arthritis. 
Nema komentara:
Objavi komentar